Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucose + moxifloxacin
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**glucose + moxifloxacin** is a combination of two substances: - **Glucose** is a simple carbohydrate used therapeutically for treating hypoglycemia and as an energy source in intravenous infusions. - **Moxifloxacin** is a fluoroquinolone antibiotic, used to treat various bacterial infections by inhibiting DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and transcription. Combined administration has been studied to assess pharmacodynamic interactions, particularly relating to cardiac electrophysiology, such as QTc interval prolongation, and to glucose/insulin metabolic effects. Moxifloxacin alone exhibits insulinotropic effects (stimulating insulin release and lowering blood glucose) and is associated with risks of dysglycemia. The combination is mostly relevant in research exploring additive effects on QTc prolongation in subjects with hyperglycemia and as a probe for metabolic/cardiac response in clinical research[1][2].
- Other names
- glucose + moxifloxacin
02
Targets
DNA gyraseKATP channel (ATP-sensitive potassium channel)Topo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on glucose + moxifloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glucose + moxifloxacin.